文献速递心脏核医学

左室室壁瘤患者心室机械不同步的预后价值:药物与手术治疗比较

Prognostic value of ventricular mechanical dyssynchrony in patients with left ventricular aneurysm: A comparative study of medical and surgical treatment.
PubMed 文献 · J Nucl Cardiol · 2020-09-09

本研究回顾性分析92例接受99mTc-甲氧基异丁基异腈门控SPECT心肌灌注显像的左室室壁瘤患者,中位随访63个月。结果显示,合并左室机械不同步的患者年心脏死亡率在手术治疗组显著低于药物治疗组(2.40% vs 6.40%,P<.05),但年MACE率无显著差异。机械不同步的发生与MACE和心脏死亡风险恶化相关,且不依赖治疗方式。

要点

  • 左室室壁瘤合并机械不同步患者年心脏死亡率手术组低于药物组(2.40% vs 6.40%,P<.05)。
  • 无机械不同步患者中,药物与手术治疗生存率和无MACE生存率无显著差异。
  • BW是全因MACE的独立预测因子(HR 1.010,P<.01),LVEF是心脏死亡的独立预测因子(HR .928,P<.05)。

核心结论

  • 左室室壁瘤合并机械不同步的患者心脏死亡和MACE风险较高,手术治疗可能较药物治疗改善心脏生存。

研究设计与样本

  • 回顾性分析92例连续接受99mTc-sestamibi门控SPECT心肌灌注显像的左室室壁瘤患者,中位随访63个月(范围1-73个月)。

主要发现

  • 合并机械不同步患者中,手术组年心脏死亡率显著低于药物组(2.40% vs 6.40%,P<.05),年MACE率无显著差异(6.61% vs 10.06%,P>.05)。
  • 无机械不同步患者中,药物与手术治疗生存率和无MACE生存率无显著差异。
  • 机械不同步与MACE和心脏死亡风险恶化相关,独立于治疗方式。
  • BW是全因MACE的独立预测因子(HR 1.010,P<.01),LVEF是心脏死亡的独立预测因子(HR .928,P<.05)。

关键数值与推荐

  • 机械不同步通过ROC分析定义,使用QGS软件分析直方图带宽(BW)。
  • 主要终点为心脏死亡,次要终点为心脏死亡与严重或急性心力衰竭的复合终点(MACE)。

临床怎么用

  • 对左室室壁瘤患者行门控SPECT评估机械不同步,有助于识别心脏死亡和MACE高风险人群。
  • 合并机械不同步的左室室壁瘤患者,手术治疗可能较药物治疗改善心脏生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic value of left ventricular (LV) mechanical dyssynchrony (MD) in patients with LV aneurysm (LVA) is unclear. This study aimed to investigate the long-term prognostic value of LVMD in LVA patients. METHODS: 92 consecutive patients who underwent 99mTc-sestamibi-gated SPECT myocardial perfusion imaging (GSPECT) were retrospectively analyzed and followed-up for a median of 63 months (range, 1-73 months). LV function and histogram bandwidth (BW) were analyzed by QGS software. LVMD was defined by ROC analysis. Cardiac death was defined as the primary endpoint, and the composite of cardiac deaths and severe or acute heart failure (MACE) as the secondary endpoint. RESULTS: The annual cardiac mortality rate of LVA patients with LVMD and treated by surgical therapy was significantly lower than those treated by medical therapy (2.40% vs. 6.40%, P < .05) but not annual MACE rate (6.61% vs. 10.06%, P > .05). In patients without LVMD, no significant difference in survival and MACE-free survival between medical and surgical treatment. In addition, the occurrence of LVMD is related to the worsen cardiac outcome in terms of MACE and cardiac death, independent of the treatment methods. BW was an independent predictor for MACE (HR 1.010, P < .01) and LVEF (HR .928, P < .05) was an independent predictor for cardiac death in all LVA patients. CONCLUSIONS: LVA patients with LVMD might be associated with high risk for cardiac death and surgical treatment might improve cardiac survival compared to medical therapy in these patients.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Lu X, Zhao M, Tian C, et al. Prognostic value of ventricular mechanical dyssynchrony in patients with left ventricular aneurysm: A comparative study of medical and surgical treatment. J Nucl Cardiol. 2020. PMID: 32909240. doi:10.1007/s12350-020-02343-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。